Skip to main content

Esketamine Nasal Spray Beneficial for Treatment-Resistant Depression

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 5, 2023 -- For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a study published in the Oct. 5 issue of the New England Journal of Medicine.

Andreas Reif, M.D., from Goethe University Hospital in Frankfurt, Germany, and colleagues conducted an open-label phase 3b randomized, active-controlled trial involving patients with treatment-resistant depression. Participants were randomly assigned to receive flexible doses of esketamine nasal spray (336 patients) or extended-release quetiapine (340 patient) both in combination with a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor. The primary end point was remission, defined as a score of 10 or less on the Montgomery-Åsberg Depression Rating Scale (MADRS), at week 8.

The researchers found that more patients in the esketamine group versus the quetiapine group had remission at week 8 (27.1 versus 17.6 percent) and had no relapse through 32 weeks after remission at week 8 (21.7 versus 14.1 percent). The percentage of patients with remission, the percentage with a treatment response, and the change in the MADRS score from baseline favored esketamine over 32 weeks of follow-up.

"These results show the superiority of esketamine nasal spray to extended-release quetiapine with respect to the primary goal of antidepressant treatment in patients with a poor prognosis, in whom treatment goals are rarely met," the authors write.

The study was funded by Janssen, the manufacturer of esketamine nasal spray.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Read this next

Risk of Suicide, Homicide Both Higher at Night

FRIDAY, June 7, 2024 -- The risk of suicide and homicide is higher at night than might be expected based on the number of people awake at that time, according to a study published...

Social Media Use Tied to Depression, but Not Sole Cause in Young Adults

FRIDAY, June 7, 2024 -- Social media use and depression are associated, but social media use is not prospectively related to the course of depressive symptoms, according to a...

Many Patients Have Discontinuation Symptoms After Stopping Antidepressants

THURSDAY, June 6, 2024 -- A considerable proportion of patients have discontinuation symptoms (e.g., dizziness, headache, nausea, insomnia, and irritability) after...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.